臺北市立萬芳醫院 泌尿科1 臺北醫學大學 醫學院 泌尿學科2 臺北市立萬芳醫院 護理部3
The Therapeutic Potential of Chemoradiotherapy Combine with Regional Hyperthermia Therapy for Locally Advanced Bladder Cancer- Phase III Clinical Trial Preliminary Data Report
Ta-Chyi Wang1, Yu-Ching Wen 1,2*, Syuan-Hao Syu1, Benjamin Chung Howe Lai1, Ke-Hsun Lin1, Yung-Wei Lin1, Chi-Hao Hsiao1, Chung Cho Hsing1, Pei Chi Yu3, Liang-Ming Lee1
1 Department of Urology, Wan Fang Hospital, Taipei Medical University
2 Department of Urology, School of Medicine, College of Medicine, Taipei Medical University
3 Department of Nursing, Wan Fang Hospital, Taipei Medical University
Purpose: To evaluate the efficiency of chemotherapy concurrent radiotherapy (CCRT) combined with locoregional hyperthermia for locally advanced bladder urothelial carcinoma.
Materials and Methods: Between Aug 2019 and Mar 2022, 10 locally advanced bladder cancer patients were enrolled in this study. Patients were treated with CCRT combined with external deep pelvic hyperthermia (using a BSD-2000 device). Deep pelvic region including bladder was heated to 41oC for 1 hour during CCRT treatment. The side effects, tumor response rate, progression-free survival, and overall survival were assessed.
Results: Ten patients were enrolled in this study. Median age was 65 years and 70% were male. The follow-up time was among 5-36 months. Complete remission (CR) in 6 patients, stable disease (SD) in one and progress disease (PD) in 3 patients. 6 patients with stage II bladder cancer were all CR. Two patients with stage III bladder cancer were SD in one and another were PD. Two patients with stage IV bladder cancer were all PD at follow-up time. One patient was dead due to disease progression. Adverse events were all minor (grade 2 or less) and all patients tolerated the whole treatment.
Conclusions: Chemotherapy concurrent radiotherapy (CCRT) combined with locoregional hyperthermia for locally advanced bladder cancer is a safe and effective treatment option. The prognosis of patients with stage II bladder cancer were CR until now.